OpenAI Acquires Orchestra Bio to Bring AI Operations to Life Sciences R&D
OpenAI has announced the acquisition of Orchestra Bio, aiming to integrate AI-driven operations into life sciences research and development. The deal is designed to help biopharmaceutical teams accelerate drug development and advance new therapies.
Official sources confirm the acquisition and its focus, allowing readers to understand OpenAI's expansion into life sciences R&D.
Also: TechCrunch · AI, The Decoder
